With Over 400 million chronic patientsIndia is one of the largest drug markets in the world. However, while most electronic pharmacists are hunting for speed, economic access remains the real challenge. Twist It took a different route: helping patients go to lower cost substitutes, a bet that now renders with new funding to about four times its previous valuation.
The six -year -old start has raised $ 85 million in a new round that includes $ 65 million in primary and $ 20 million in ACCEL secondary funding, along with the participation of Peak XV partners. TechCrunch mentioned Accel for the first time with Back Truemeds last year. Existing Westbridge Capital and Infoedge Ventures also participated.
The new round has boosted Truemeds valuation to over $ 400 million, out of $ 110 million in the last round two years ago.
Founded in 2019, the Truemeds entered the market at a time when India’s online pharmacist was already full of major players offering abrupt discounts on branded generics. However, some of these companies fought to maintain the early dynamic-for example, Prosus Ventures, for example, saw the $ 5.6 billion valuation drop in less than $ 600 million, while $ 1mg was acquired by Tata Digital, part of the TATA group. Instead of competing with the head, the founders of Truemeds chose to focus on a relatively specialized section: General medicines.
“There is no way to train the user that you can have more affordable options if you can’t afford these drugs,” said co -founder Akshat Nayyar (depicted above, left) in an interview. “There we felt that no one in the value chain worked for it, and we can bridge this gap.”
The Mubai -based component is general alternatives to consumers for the branded medicines they need. This ultimately helps consumers save money, as generic drugs are usually more affordable than their branded versions due to cost efficiency in their development process.
TrueMeds says its differentiated approach has paid, with revenue rising over 66% annually to $ 5 billion ($ 57 million) in the last financial year. The start says it has more than 50% of its revenue after 12 months and now serves an average of 500,000 customers each month, with a total of 3 million customers to date. In addition, he says it now serves more than 20,000 postal codes across the country, with over 75% of its customers coming from Class-2 cities and beyond.
TechCrunch event
Francisco
|
27-29 October 2025
However, customer training on alternatives to their prescription medicines – and persuade them to go from branded drugs to generic – remains a challenge.
“Because you are getting anchored at the price of your prescription brand and when you see suddenly lower price, you want to know why it’s low,” Nayyar told TechCrunch.
Increasing discounts while competitors reduce
While today’s electronic pharmacists are hunting speed above saving, the early playbook of the sector was different. Electronic pharmacies in India are used to offer discounts of up to 25% to attract customers. But Nayyar said this was reduced to 20% and then 15% – the new average – as most burnt cash to get new customers and rotate in faster delivery as their main differentiate.
TrueMeds has proceeded in the opposite direction, increasing its average discounts from 29% to 32% in the last 12 months. For an average user who changes brands on the platform, savings reaches 47% for their medicine, the company says.
This comes from Truemeds’ deep procurement relationships with pharmacist companies, where the start uses its technology to give manufacturers better demanding demand, helping them design production more effectively for upcoming quarters, he said.
The start is also based on its own logistics in some of the large cities that operate and uses low -cost logistics partners for the rest.
“We believe that the delivery model of our four hours is more than sufficient than the chronic patient’s point of view,” Nayyar said. “You are able to make more scheduled purchases in this way but we want to do it in the most effective way and get more and more discounts on the end user rather than [focus on] The fastest delivery for this issue. ”
Next up: Adaptation and diagnosis of lower minimum resource
As Truemeds has to persuade customers to choose generic for branded medicines, it goes through deeper consultations with them. It is already conducting 10-12 million consultations a year. The start has developed an algorithm over the years that examines various parameters to propose exactly alternatives to branded medicines required by a customer. It considers shades like whether the drug is sugar -coated if it is a young patient, where it is manufactured and if the plant is GMP certified, among other things. The boot also has a chatbot to quickly address some user questions.
Much more is on the march map. The company plans to develop a AI -based system that adapts customer behavior -based conversations and previous interactions with general alternatives. It also opens a Bangalore office, and dedicated at least 20% of its capital to engineering and product development.
In addition to medicines, Truemeds plans to introduce diagnostics through corporate relationships with national pathology laboratories by designing laboratory testing services in certain cities in the Class-2 in the next three to four months.
“The main mission remains the same, which makes health care accessible to the end user,” the co -founder said. “It started with medicines, now that the model has been established, we will continue to scale. At the same time we also want to see if we can do something similar on the diagnostic front, where we can be the lowest cost provider of at least the most common tests.”
The start is also planning to increase the Center Fulfillment Center by 300% – from 19 today – in the next 12 months, with the aim of deepening its presence in existing markets.
Before this round, the TrueMeds raised $ 50 million and still have 30-35% of this capital in the bank, Nayyar said.
The start has a workforce of 2,800 people, with 250 based in the Bombay office.
